Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation

J Invest Dermatol. 2021 Apr;141(4):930-933. doi: 10.1016/j.jid.2020.07.036. Epub 2020 Sep 22.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Anilides / administration & dosage*
  • Anilides / adverse effects
  • Anilides / pharmacokinetics
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Carcinoma, Basal Cell / diagnosis
  • Carcinoma, Basal Cell / drug therapy*
  • Carcinoma, Basal Cell / pathology
  • Computer Simulation
  • Datasets as Topic
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Middle Aged
  • Models, Biological*
  • Neoplasm Staging
  • Pyridines / administration & dosage*
  • Pyridines / adverse effects
  • Pyridines / pharmacokinetics
  • Skin / drug effects
  • Skin / pathology
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Treatment Outcome
  • Tumor Burden / drug effects

Substances

  • Anilides
  • Antineoplastic Agents
  • HhAntag691
  • Pyridines